TET2 and neoplasm: The mutational landscape of AITL/TCL‐TFH has been well characterized, with frequent early occurrence of TET2 and DNMT3A mutations in haematopoietic stem cells, and RHOA‐G17 and IDH2‐R172 mutations as later pathogenic events in tumour cells only.4, 5